Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease

被引:75
作者
Yamashita, Tomoya [1 ]
Sasaki, Naoto [1 ]
Kasahara, Kazuyuki [1 ]
Hirata, Ken-ichi [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, Kobe, Hyogo 6500017, Japan
基金
日本学术振兴会;
关键词
Inflammation; Vaccine; Regulatory T cell; Intestinal immunity; REGULATORY T-CELLS; DECREASES ATHEROSCLEROSIS; MONOCLONAL-ANTIBODY; ANTI-CD3; ANTIBODY; DENDRITIC CELLS; MECHANISMS; IMMUNIZATION; INDUCTION; MICE; INFLAMMATION;
D O I
10.1016/j.jjcc.2015.02.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is believed to be a chronic inflammation of the arterial wall and various immune cells of innate and adaptive immunity involves in the pathogenesis of atherosclerosis. Based on this notion, several anti-inflammatory strategies for prevention of atherosclerosis have been examined mainly using animal models. Vaccination or mucosal immunization with athero-antigens comes under candidate therapeutic methods for antigen-specific prevention of atherosclerosis. Immune suppression mediated by regulatory T cells (Tregs) could be another method to regulate pathogenic chronic inflammation in atherogenesis. Inducible Tregs are reported to differentiate peripherally in the intestine and we have been interested in the oral tolerance, in which not only Tregs but also tolerogenic dendritic cells play crucial roles. We demonstrated that modulation of the intestinal immunity including oral tolerance could be a novel therapy against atherosclerosis. Further, downregulation of effector T cell response and/or Treg predominant condition was shown to induce atherosclerosis regression and inhibit the progression of aneurysm. In clinical situations, none of the approaches to specifically and directly treat inflammation to prevent cardiovascular events or reduce atherosclerosis in human individuals were successful, although high-sensitive C-reactive protein is shown to have a strong relationship with recurrent events of cardiovascular diseases in several randomized clinical trials. Now two randomized placebo-controlled clinical trials evaluating anti-inflammatory agents are being conducted in the USA and Canada to clarify whether targeting the inflammation itself will reduce cardiovascular events and risks. In this review, we present the current understanding of anti-inflammatory and immune-modulation therapies against atherosclerosis and discuss the future perspectives. (C) 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 54 条
[1]   Natural regulatory T cells control the development of atherosclerosis in mice [J].
Ait-Oufella, H ;
Salomon, BL ;
Potteaux, S ;
Robertson, AKL ;
Gourdy, P ;
Zoll, J ;
Merval, R ;
Esposito, B ;
Cohen, JL ;
Fisson, S ;
Flavell, RA ;
Hansson, GK ;
Klatzmann, D ;
Tedgui, A ;
Mallat, Z .
NATURE MEDICINE, 2006, 12 (02) :178-180
[2]   Effects of antibiotic therapy on outcomes of patients with coronary artery disease - A meta-analysis of randomized controlled trials [J].
Andraws, R ;
Berger, JS ;
Brown, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (21) :2641-2647
[3]   TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes [J].
Belghith, M ;
Bluestone, JA ;
Barriot, S ;
Mégret, J ;
Bach, JF ;
Chatenoud, L .
NATURE MEDICINE, 2003, 9 (09) :1202-1208
[4]   Mechanisms of Plaque Formation and Rupture [J].
Bentzon, Jacob Fog ;
Otsuka, Fumiyuki ;
Virmani, Renu ;
Falk, Erling .
CIRCULATION RESEARCH, 2014, 114 (12) :1852-1866
[5]   CD3-specific antibodies: a portal to the treatment of autoimmunity [J].
Chatenoud, Lucienne ;
Bluestone, Jeffrey A. .
NATURE REVIEWS IMMUNOLOGY, 2007, 7 (08) :622-632
[6]   Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].
Chen, WJ ;
Jin, WW ;
Hardegen, N ;
Lei, KJ ;
Li, L ;
Marinos, N ;
McGrady, G ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886
[7]   NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals [J].
Duewell, Peter ;
Kono, Hajime ;
Rayner, Katey J. ;
Sirois, Cherilyn M. ;
Vladimer, Gregory ;
Bauernfeind, Franz G. ;
Abela, George S. ;
Franchi, Luigi ;
Nunez, Gabriel ;
Schnurr, Max ;
Espevik, Terje ;
Lien, Egil ;
Fitzgerald, Katherine A. ;
Rock, Kenneth L. ;
Moore, Kathryn J. ;
Wright, Samuel D. ;
Hornung, Veit ;
Latz, Eicke .
NATURE, 2010, 464 (7293) :1357-U7
[8]   Regulatory/Effector T-Cell Ratio Is Reduced in Coronary Artery Disease [J].
Emoto, Takuo ;
Sasaki, Naoto ;
Yamashita, Tomoya ;
Kasahara, Kazuyuki ;
Yodoi, Keiko ;
Sasaki, Yoshihiro ;
Matsumoto, Takuya ;
Mizoguchi, Taiji ;
Hirata, Ken-ichi .
CIRCULATION JOURNAL, 2014, 78 (12) :2935-2941
[9]   Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis [J].
Everett, Brendan M. ;
Pradhan, Aruna D. ;
Solomon, Daniel H. ;
Paynter, Nina ;
MacFadyen, Jean ;
Zaharris, Elaine ;
Gupta, Milan ;
Clearfield, Michael ;
Libby, Peter ;
Hasan, Ahmed A. K. ;
Glynn, Robert J. ;
Ridker, Paul M. .
AMERICAN HEART JOURNAL, 2013, 166 (02) :199-+
[10]   Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences [J].
Fredrikson, GN ;
Söderberg, I ;
Lindholm, M ;
Dimayuga, P ;
Chyu, KY ;
Shah, PK ;
Nilsson, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (05) :879-884